Disitamab Vedotin provides a HER2-targeting antibody-drug conjugate (ADC) for cancer and oncology research and specifically combines a HER2-directed monoclonal antibody with monomethyl auristatin E (MMAE), supporting studies of HER2-targeted cytotoxicity and ADC mechanisms.
Key Features and Benefits
- HER2-Targeting ADC: Combines a HER2-directed monoclonal antibody with the cytotoxic MMAE payload.
- MMAE Payload: Contains monomethyl auristatin E, a potent microtubule-disrupting agent specifically studied in ADC research.
- HER2 Recognition: Supports investigation of HER2 expression, antibody binding, internalization, and tumor-targeting mechanisms.
- Cleavable Linker: Uses a protease-cleavable linker specifically designed to facilitate intracellular MMAE release after cellular uptake.
- Targeted Payload Delivery: Supports investigation of antibody-mediated MMAE delivery to HER2-expressing cancer cells.
- Microtubule Disruption: MMAE inhibits microtubule dynamics, specifically supporting studies of ADC-mediated cytotoxic responses.
- ADC Research Platform: Enables investigation of target engagement, internalization, payload release, and cellular activity.
Applications
- HER2-Positive Cancer Research: Supports studies involving tumors with elevated HER2 expression.
- HER2-Low Cancer Research: Useful for investigating ADC strategies in cancer models with lower levels of HER2 expression.
- Breast Cancer Research: Supports studies of HER2-directed ADC mechanisms in relevant breast cancer models.
- Gastric Cancer Research: Useful for investigating HER2-targeted approaches in gastric and gastroesophageal cancer models.
- Urothelial Cancer Research: Supports investigation of HER2-targeted ADC strategies in urothelial cancer models.
- ADC Research: Useful for studying antibody targeting, internalization, payload delivery, and cytotoxic activity.
- Mechanism-of-Action Studies: Supports investigation of HER2 targeting and MMAE-mediated microtubule disruption.
Storage and Handling
- Storage: Store according to the product specification under recommended temperature conditions. Protect from excessive heat and repeated freeze-thaw cycles.
- Handling: Handle using appropriate procedures for antibody-drug conjugates and cytotoxic research materials. Maintain conditions that preserve protein and conjugate stability.
Disitamab Vedotin combines HER2-directed antibody targeting with the microtubule-disrupting MMAE payload and specifically supports HER2-positive and HER2-low cancer, ADC, targeted drug delivery, and oncology research.
AxisPharm offers 5000+ PEG Linkers with high purity. Different kinds of PEG Reagents may be available by custom synthesis.
